The FDA granted sibeprenlimab accelerated approval for nephropathy after data showed it cut IgA nephropathy proteinuria by about 50% via APRIL inhibition.
Jackson Peter Kim, MD
Advertisement
Jackson Peter Kim, MD, clinical assistant professor in the Division of Nephrology at Stanford Health Care
Articles by Jackson Peter Kim, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS
2
Orca-T Gains FDA Approval for Matched Donor Stem Cell Transplant
3
House Panel Advances Bills to Expand Veterans’ Health Care Access
4
Racial Gaps in Cancer Pain Management Persist in Community Care: Ila Sruti, MPH
5